# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Coeptis Therapeutics (NASDAQ:COEP) reported quarterly losses of $(1.17) per share. This is a 26.88 percent increase over losses...
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and bioph...
SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc.
NUBURU Poised to Finalize Strategic Acquisition and Prepare the Adoption of Advanced Technology, Artificial Intelligence & ...